Updated:
Abingworth
Abingworth invests in life sciences companies from seed through late stages across North America and Europe.
Abingworth
Abingworth was established to back life sciences entrepreneurs. The firm advances companies developing novel treatments from early proof of concept through commercialization. Investment activity spans seed, early, growth, and late stages. Asset classes include private equity, venture, and public equity via VIPEs. Confirmed positions focus on biotherapeutics, small molecules, vaccines, and platform technologies. The firm maintains a geographic footprint across North America and Europe. It executes direct co-investments and SPVs rather than broad fund commitments. Team size and additional offices remain undisclosed. No adjacent philanthropic vehicles or club memberships appear in available records. No operational events from the last 24 months have been confirmed. Abingworth maintains a hybrid mandate that combines venture formation with clinical co-development support for portfolio companies progressing through regulatory stages.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Menlo Park
Corporate office
Menlo Park, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Abingworth?
No named principals or investment committee members appear in public records.
How does Abingworth source proprietary deal flow?
The firm partners directly with entrepreneurs developing therapeutics and platform technologies.
Does Abingworth participate in fund commitments or only direct deals?
Activity centers on direct co-investments and SPVs rather than primary fund commitments.
What investment stages does Abingworth typically target?
The firm covers seed, early stage, growth, and late stage opportunities.
Which sectors does Abingworth explicitly avoid?
No explicit avoidance sectors are stated beyond the life sciences focus.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: